AZD5004 drug interaction study: no cure, just data
NCT ID NCT06948747
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how a new drug called AZD5004 affects the way the body processes several common medicines, including statins (for cholesterol) and repaglinide (for diabetes), in healthy adults aged 18 to 55. It also checked how another drug, erythromycin, affects AZD5004. The goal was simply to gather safety and interaction information, not to treat any disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Brooklyn, Maryland, 21225, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common antifungal change how an experimental drug acts?
- Can a new injection help tackle obesity? a safety trial begins
- Will a new pill formula absorb the same? a trial puts it to the test
- Can a new drug tame Alzheimer's? early trial aims to find out
- Could sitting too much alter your nervous system?
- Could a cancer drug alter Metformin's effects? a trial investigates